
Opinion|Videos|June 10, 2025
The Use of Ultra-Low PSA in Specific Patient Profiles
Author(s)Neal Shore, MD, FACS
Research explores the effectiveness of Aerote in treating metastatic hormone-sensitive prostate cancer, focusing on patient subgroups and genetic factors.
Advertisement
Episodes in this series

Patient Selection for Ultra-Low PSA Monitoring
Key Themes:
- Identification of patient profiles most likely to benefit from ultra-low PSA monitoring
- Relevance for specific risk categories
- Potential applications in high-volume disease or triplet therapy
Expert Insights:
- Dr Shore identified specific patient profiles or risk categories where the ultra-low PSA threshold might be particularly valuable.
He discussed its potential relevance for patients with high-volume disease, those receiving triplet therapy, or patients demonstrating rapid initial PSA declines.
Advertisement
Related to this article

Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.

Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.

An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Variation in PSMA PET Adoption for Prostate Cancer Care
3
FDA grants 510(k) clearance to OpenFlo urinary catheter
4
FDA grants fast track designation to VIR-5500 for mCRPC
5
